Storandt, M.H.; Gile, J.J.; Palmer, M.E.; Zemla, T.J.; Ahn, D.H.; Bekaii-Saab, T.S.; Jin, Z.; Tran, N.H.; Mahipal, A.
Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers 2022, 14, 5173.
https://doi.org/10.3390/cancers14215173
AMA Style
Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A.
Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers. 2022; 14(21):5173.
https://doi.org/10.3390/cancers14215173
Chicago/Turabian Style
Storandt, Michael H., Jennifer J. Gile, Mathias E. Palmer, Tyler J. Zemla, Daniel H. Ahn, Tanios S. Bekaii-Saab, Zhaohui Jin, Nguyen H. Tran, and Amit Mahipal.
2022. "Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma" Cancers 14, no. 21: 5173.
https://doi.org/10.3390/cancers14215173
APA Style
Storandt, M. H., Gile, J. J., Palmer, M. E., Zemla, T. J., Ahn, D. H., Bekaii-Saab, T. S., Jin, Z., Tran, N. H., & Mahipal, A.
(2022). Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers, 14(21), 5173.
https://doi.org/10.3390/cancers14215173